文献速递甲状腺疾病

维莫非尼联合抗ErbB3单克隆抗体CDX-3379增强BRAF突变型碘难治性甲状腺癌摄碘能力的先导性临床试验结果

Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.
PubMed 文献 · Thyroid · 2022-01-01

本先导性临床试验纳入7例BRAFV600E突变型碘难治性甲状腺癌患者,评估维莫非尼联合CDX-3379的安全性及增强摄碘能力。6例可评估患者中无CDX-3379相关3/4级毒性,5例摄碘增加,4例摄碘增加足以进行131I治疗;6个月时2例部分缓解、2例疾病进展。作者认为研究达到主要终点,提示联合方案安全有效,但需更大规模试验验证。

要点

  • 维莫非尼联合CDX-3379在BRAFV600E碘难治性甲状腺癌中未观察到CDX-3379相关3/4级毒性。
  • 6例可评估患者中5例治疗后摄碘增加,其中4例摄碘增加足以接受治疗性131I。
  • 6个月时2例达部分缓解、2例疾病进展;无增强摄碘的患者及另一例耐药肿瘤中检出ARID2突变。

核心结论

  • 研究达到主要终点,提供维莫非尼联合CDX-3379增强摄碘安全有效的初步证据。
  • 小队列的临床前数据及基因组分析提示,SWI/SNF基因突变应作为再分化治疗耐药潜在标志物进行研究。
  • 作者认为需在更大规模试验中进一步评估维莫非尼联合CDX-3379作为再分化治疗。

研究设计与样本

  • 先导性临床试验,纳入BRAFV600E突变型碘难治性甲状腺癌患者7例,6例可评估主要终点。
  • 基线及治疗5周后行促甲状腺激素刺激的124I PET/CT评估摄碘,治疗方案为口服维莫非尼960 mg每日两次单药1周,后联合静脉CDX-3379 1000 mg每2周一次。
  • 第二次PET/CT显示足够124I摄取者接受治疗性131I,同时继续维莫非尼联合CDX-3379,所有治疗于2天后停止。
  • 通过血清甲状腺球蛋白测定和影像学监测治疗反应。
  • 主要终点为维莫非尼联合CDX-3379的安全性和耐受性,以及治疗后摄碘增强足以进行131I治疗的患者比例。

主要发现

  • 共入组7例患者,6例可评估主要终点。
  • 未观察到CDX-3379相关的3级或4级毒性。
  • 5例患者治疗后摄碘增加,其中4例摄碘增加足以进行治疗性131I。
  • 6个月时,2例接受131I后达部分缓解,2例疾病进展。
  • 5例患者二代测序均显示合并端粒酶逆转录酶启动子改变;1例治疗后摄碘未增强的患者及另1例研究外采样的碘抵抗肿瘤患者中发现SWI/SNF基因ARID2有害突变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 小队列。
  • 作者认为需在更大规模试验中进一步评估维莫非尼联合CDX-3379作为再分化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Oncogenic activation of mitogen-activated protein kinase (MAPK) signaling is associated with radioiodine refractory (RAIR) thyroid cancer. Preclinical models suggest that activation of the receptor tyrosine kinase erbB-3 (HER3) mitigates the MAPK pathway inhibition achieved by BRAF inhibitors in BRAFV600E mutant thyroid cancers. We hypothesized that combined inhibition of BRAF and HER3 using vemurafenib and the human monoclonal antibody CDX-3379, respectively, would potently inhibit MAPK activation and restore radioactive iodine (RAI) avidity in patients with BRAF-mutant RAIR thyroid cancer. Methods: Patients with BRAFV600E RAIR thyroid cancer were evaluated by thyrogen-stimulated iodine-124 (124I) positron emission tomography-computed tomography (PET/CT) at baseline and after 5 weeks of treatment with oral vemurafenib 960 mg twice daily alone for 1 week, followed by vemurafenib in combination with 1000 mg of intravenous CDX-3379 every 2 weeks. Patients with adequate 124I uptake on the second PET/CT then received therapeutic radioactive iodine (131I) with vemurafenb+CDX-3379. All therapy was discontinued two days later. Treatment response was monitored by serum thyroglobulin measurements and imaging. The primary endpoints were safety and tolerability of vemurafenib+CDX-3379, as well as the proportion of patients after vemurafenb+CDX-3379 therapy with enhanced RAI incorporation warranting therapeutic 131I. Results: Seven patients were enrolled; six were evaluable for the primary endpoints. No grade 3 or 4 toxicities related to CDX-3379 were observed. Five patients had increased RAI uptake after treatment; in 4 patients this increased uptake warranted therapeutic 131I. At 6 months, 2 patients achieved partial response after 131I and 2 progression of disease. Next-generation sequencing of 5 patients showed that all had co-occurring telomerase reverse transcriptase promoter alterations. A deleterious mutation in the SWItch/Sucrose Non-Fermentable (SWI/SNF) gene ARID2 was discovered in the patient without enhanced RAI avidity after therapy and an RAI-resistant tumor from another patient that was sampled off-study. Conclusions: The endpoints for success were met, providing preliminary evidence of vemurafenib+CDX-3379 safety and efficacy for enhancing RAI uptake. Preclinical data and genomic profiling in this small cohort suggest SWI/SNF gene mutations should be investigated as potential markers of resistance to redifferentiation strategies. Further evaluation of vemurafenib+CDX-3379 as a redifferentiation therapy in a larger trial is warranted (ClinicalTrials.gov: NCT02456701).

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Tchekmedyian V, Dunn L, Sherman E, et al. Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. Thyroid. 2022. PMID: 35045748. doi:10.1089/thy.2021.0565

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。